Jason Orestes

A former writer for TheStreet, Jason is an ardent follower of financial markets and macro-developments and enjoys disseminating his research and due diligence in an effort to both spark ideas for alpha and to help corroborate the findings of others. He enjoys taking recent macro events, distilling the underlying cause, and extrapolating the impact to be had on public companies.

Some of his other writings can be found on Seeking Alpha here

 

Recent Articles By The Author

How to Invest in the Face of Deflation in the U.S. Economy

How to Invest in the Face of Deflation in the U.S. Economy

All central banks attempt to avoid deflation like the plague. But why exactly is it so detrimental and how can it affect your investments?

AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?

AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech?

AcelRx shareholders were burned yet again when the company announced new clinical trials were required for its flagship drug. What's to come for this struggling biotech company?

3 Reasons the U.S. Dollar Will Continue to Get Stronger

3 Reasons the U.S. Dollar Will Continue to Get Stronger

The U.S. dollar has been one of the best performing currencies within the last year, but what has catalyzed this strength and will it continue?

What Is the Rationale Behind Owning a Negative-Yield Bond?

What Is the Rationale Behind Owning a Negative-Yield Bond?

A negative-yield bond literally means you are paying a government for the right to loan them money. What's the logic behind owning such a counterintuitive investment?

How the Death of Saudi King Abdullah Could Affect Oil Prices

How the Death of Saudi King Abdullah Could Affect Oil Prices

There should be no alterations in oil policy from Saudi Arabia, but be cognizant of any cabinet changes, specifically oil minister Al-Naimi.

Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?

Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection?

AcelRx Pharmaceuticals was hit with an FDA rejection and is due to resubmit their drug this quarter; should investors stay away or is there an opportunity to be had?

Super Smart Ways to Intelligently Invest in Communist Cuba

Super Smart Ways to Intelligently Invest in Communist Cuba

Bullish on Cuba? A fund and some individual stocks you want to consider.

How Much GE, ExxonMobil and Other Big Firms Are Exposed to Russia

How Much GE, ExxonMobil and Other Big Firms Are Exposed to Russia

Plunging oil prices and the skidding ruble have wreaked havoc on the Russian economy, creating major worries in global markets.

Who Are the Winners and Losers in a World of Plunging Oil Prices?

Who Are the Winners and Losers in a World of Plunging Oil Prices?

The beneficiaries and those feeling the pain of declining oil prices aren't as straightforward as you think.

Does OPEC's Meeting Still Matter for Energy Stock Investors?

Does OPEC's Meeting Still Matter for Energy Stock Investors?

Maybe only for the short-term price of oil.